The Chemical Data

Life-Sciences-Firms-Embrace-AI-and-Partnerships-to-Drive-Change_

Life Sciences Firms Embrace AI and Partnerships to Drive Change

Life Sciences Firms Turn to AI and Strategic Partnerships to Accelerate Digital Transformation Life sciences companies are embracing artificial intelligence (AI), automation, and strategic collaborations to drive agility, innovation, and patient-centricity, according to the latest research report by Information Services…

Read MoreLife Sciences Firms Embrace AI and Partnerships to Drive Change
Alpha Cognition Reports Positive Preclinical Results for ALPHA-1062 in Mild TBI Model

Alpha Cognition Reports Positive Preclinical Results for ALPHA-1062 in Mild TBI Model

Alpha Cognition Reports Promising Preclinical Results for ALPHA-1062 in Military-Related Mild TBI Model Alpha Cognition Inc., a biopharmaceutical company focused on developing innovative treatments for neurodegenerative disorders, has announced encouraging preclinical data supporting the continued development of ALPHA-1062 for the…

Read MoreAlpha Cognition Reports Positive Preclinical Results for ALPHA-1062 in Mild TBI Model
Vertex Gains EU Approval for ALYFTREK®, a New Daily Cystic Fibrosis Treatment

Vertex Gains EU Approval for ALYFTREK®, a New Daily Cystic Fibrosis Treatment

Vertex Secures EU Approval for ALYFTREK®, a New Once-Daily Treatment for Cystic Fibrosis Vertex Pharmaceuticals announced that the European Commission (EC) has approved ALYFTREK® (deutivacaftor/tezacaftor/vanzacaftor) for the treatment of cystic fibrosis (CF) in patients aged 6 years and older who…

Read MoreVertex Gains EU Approval for ALYFTREK®, a New Daily Cystic Fibrosis Treatment
OS Therapies Reports Positive OST-HER2 Survival Data at Osteosarcoma Conference

OS Therapies Reports Positive OST-HER2 Survival Data at Osteosarcoma Conference

OS Therapies Reports Positive OST-HER2 Survival Data at Osteosarcoma Conference OS Therapies a clinical-stage biopharmaceutical company specializing in immunotherapy and Antibody Drug Conjugates (ADCs), has announced encouraging clinical data from its ongoing Phase 2b clinical trial of OST-HER2, a promising…

Read MoreOS Therapies Reports Positive OST-HER2 Survival Data at Osteosarcoma Conference